Plain-English translation of NCT06549465 on ClinicalTrials.gov ↗ ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new treatment called rosopatamab tetraxetan — a radioactive antibody designed to find and attack prostate cancer cells that have spread to other parts of the body. The medication works by targeting a specific protein found on prostate cancer cells, then delivering radiation directly to those cells. Researchers are trying to figure out the best dose and treatment schedule to help patients with advanced prostate cancer that no longer responds to standard hormone therapies.
Standard hormone treatments stop working for many men with advanced prostate cancer. This trial exists to see whether this new radioactive antibody can help patients whose cancer has become resistant to current treatments.
You likely qualify if…
You likely don't qualify if…
The study has four phases. First, you'll receive an initial imaging dose to map where the medication travels in your body. Depending on your treatment history, you'll then be assigned to one of three treatment phases, receiving injections of the medication either once, twice (two weeks apart), or three times (with the third dose about 12 weeks later). Throughout the trial, you'll attend multiple study visits that include blood draws, heart monitoring with an ECG, imaging scans, and physical examinations to monitor how well the treatment works and check for any side effects.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
United States